Thursday, July 7 2022

Press release Nicox will participate in financial, pharmaceutical and scientific events in the first half of 2022

January 27, 2022
Sophia-Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), an international society of ophthalmology, today announced that members of the management team will attend the following financial, pharmaceutical and scientific conferences in Europe and the United States in the coming months :

Financial and Pharmaceutical Industry Conferences

  • BIOMED Event – March 8, 2022 – Paris, France
  • SmallCap event – April 4-5, 2022, Paris, France
  • Invest Access Event – April 4-5, 2022 – Paris, France
  • BIO International Convention – June 13-16, 2022 – San Diego, USA
  • Spring Midcap Event – June 23-24, 2022 – Paris, France

Members of the management team will be available for one-on-one meetings at these events.

Scientific conferences

  • Glaucoma 360 – February 10-12, 2022, San Francisco, CA, USA
  • American Glaucoma Society (AGS) 2022 Annual Meeting – March 3-6, 2022 – Nashville, TN, USA
  • American Society of Cataract and Refractive Surgery (ASCRS) 2022 Annual Meeting – April 22-26, 2022 – Washington, DC, USA
  • Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting – May 1-5, 2022 – Denver, CA, USA, May 11-12, 2022 – Virtual
  • 15and European Glaucoma Society (EGS) Congress – June 4-8, 2022 – Athens, Greece

About Nicox Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve eye health. Nicox’s lead clinical development program is NCX 470, a novel nitric oxide-donating prostaglandin analogue, intended to reduce intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox Generates Revenues from VYZULTA® in Glaucoma, Licensed Worldwide Exclusively to Bausch + Lomb, and ZERVIATE® in Allergic Conjunctivitis, Licensed in Multiple Geographies, Including Eyevance Pharmaceuticals, LLC, USA and Ocumension Therapeutics in China and most Southeast Asian markets. .
Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indices.

For more information about Nicox, its products or its pipeline, please visit: www.nicox.com. Analyst coverage Bryan, Garnier & Co Dylan Van Haaften Paris, France
Edison Investment Research Pooya Hemami London, United Kingdom
HC Wainwright & Co Yi Chen New York, USA
Kepler Cheuvreux Damien Choplain Paris, France The opinions expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. In addition, the information contained in their reports may not be correct or up to date. Nicox disclaims any obligation to correct or update information contained in analyst reports.

contacts Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Business Development Manager
T +33 (0)4 97 24 53 00
[email protected] Investors & Media
United States and Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
[email protected] Forward-looking statements The information contained in this document is subject to change without notice. This information includes forward-looking statements. These forward-looking statements are not guarantees of future performance. These statements are based on the current expectations or beliefs of the management of Nicox SA and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, advisors or agents, do not undertake and have no obligation to provide any updates or revise any forward-looking statements.

The risk factors likely to have a significant effect on Nicox’s business are presented in the 3rd chapter of ‘Universal registration document, annual financial report and management report 2020‘ filed with the French Financial Markets Authority (AMF) on March 1, 2021 and in the 2n/a chapter of the amendment to the “Universal Registration Document, annual financial report and management report 2020” filed with the AMF on December 9, 2021 which are available on the Nicox website (www.nicox.com). Nicox S.A.
Longship 2
Building D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

Attachment

main logo

Previous

Global esports market expected to grow 16% through 2026

Next

Popular Grimsby comic book store will move after nearly two decades

Check Also